Experimental HIV Drugs
Experimental HIV Drugs
CROI 2017: Several New Candidates in HIV Drug Pipeline Discussed at Conference
- Details
- Category: Experimental HIV Drugs
- Published on Saturday, 04 March 2017 00:00
- Written by Liz Highleyman
This year's Conference on Retroviruses and Opportunistic Infections (CROI), held last month in Seattle, included presentations on several new investigational antiretroviral drugs in development, reflecting a more robust pipeline than we have seen in recent years.
CROI 2017: New HIV Capsid Inhibitors Show High Potency and Prolonged Activity in Early Studies
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 27 February 2017 00:00
- Written by Liz Highleyman
A novel type of antiretroviral drug that interferes with the assembly and disassembly of the HIV capsid, which encloses the genetic blueprint of the virus, may offer a new potent and long-acting treatment option if it continues to look promising in larger studies, according to a presentation at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.
CROI 2017: Integrase Inhibitor Bictegravir Matches Dolutegravir for First-Line HIV Treatment
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 14 February 2017 00:00
- Written by Liz Highleyman
Bictegravir, an investigational integrase inhibitor from Gilead Sciences, was highly potent, well tolerated and worked as well as dolutegravir (Tivcay) in a Phase 2 clinical trial, according to study results presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle and published online in The Lancet HIV.
CROI 2017: Monoclonal Antibodies Show Promise for HIV+ People with Few Treatment Options
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 21 February 2017 00:00
- Written by Liz Highleyman
A pair of long-acting monoclonal antibodies that prevent HIV from entering human cells -- ibalizumab and PRO 140 -- may offer new treatment options for people with highly resistant virus and limited treatment options, researchers reported at the Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.
HIV Glasgow: Long-Acting HIV Fusion Inhibitor Albuvirtide Regimen Matches Standard Therapy
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 07 November 2016 00:00
- Written by Keith Alcorn
A new fusion inhibitor, albuvirtide, under development in China, combined with a boosted protease inhibitor, proved just as effective as a triple regimen of lopinavir/ritonavir plus 2 NRTIs for treatment-experienced HIV patients, according to a report at the International Congress on Drug Therapy in HIV Infection last month in Glasgow.
More Articles...
- IDWeek 2016: Ibalizumab Monoclonal Antibody Looks Promising for HIV Patients Left Behind
- AIDS 2016: Long-Acting Injectable Drugs Work Well for HIV Maintenance Therapy
- ASM Microbe 2016: PRO 140 Antibody Injections Maintain Viral Suppression Off ART
- FDA Approves Descovy TAF Combination Pill for HIV Treatment, Not Yet for PrEP
Web Design and Development by